Table II.
Drug stability results over a period of 3 mo obtained for Formulation B [4 mL of ketamine (100 mg/mL) and 1 mL of xylazine (20 mg/mL)]
| Time (mo) | Room temperature | |||||
|---|---|---|---|---|---|---|
|
| ||||||
| Ketamine | Xylazine | |||||
|
|
|
|||||
| % remaining | SD | %CV | % remaining | SD | %CV | |
| 0 | 100.00 | 1.66 | 1.7% | 100.00 | 7.57 | 7.6% |
| 1 | 94.72 | 0.60 | 0.6% | 89.89* | 0.67 | 0.7% |
| 2 | 87.50* | 2.04 | 2.3% | 86.85* | 2.24 | 2.6% |
| 3 | 88.73* | 0.22 | 0.2% | 83.19* | 3.03 | 3.7% |
| 4°C | ||||||
| 0 | 100.00 | 1.60 | 1.6% | 100.00 | 4.89 | 4.9% |
| 1 | 101.72 | 1.67 | 1.6% | 107.27 | 6.50 | 6.1% |
| 2 | 105.79 | 1.00 | 0.9% | 115.17 | 6.04 | 5.2% |
| 3 | 105.45 | 0.35 | 0.3% | 109.70 | 4.94 | 4.5% |
*
Concentration remaining < 90% of initial concentration.
P < 0.0001 [one-way analysis of variation (ANOVA) with post-hoc Dunnett’s test].
SD — standard deviation; CV — coefficient of variation.